Why drug targeting of the hTERT G-Quadruplex in the promoter produces rapid induction of apoptosis specifically in cancer cells
29 August 2018
Laurence H. Hurley, PhD
Cancer Center, University of Arizona, USA
Host: Alexandra Paulo
Faculdade de Farmácia, Universidade de Lisboa
Professor Hurley’s long-time research interest is in molecular targeting of DNA. He was the discoverer and developer, with Cylene Pharmaceuticals, of Quarfloxin, the first-in-class G-quadruplex-interactive molecule that reached phase 2 clinical trials. He is also the scientific founder and CEO of TetraGene, a biotech company that focuses on targeting secondary DNA structures to modulate expression of undruggable targets, including MYC, BCL2, kRAS, and hTERT. As a member of the developmental therapeutics program, he is actively involved in translational research.